

# PHARMACOLOGY

## Principles of Pharmacotherapeutics

Independent Study Course 28.4.3

*Reissued from ISC 16.1.1*

Suzanne L. Tinsley, PT, PhD

Louisiana State University Health Sciences Center  
Shreveport, LA



CONTINUING PHYSICAL THERAPY EDUCATION

ACADEMY OF  
**ORTHOPAEDIC**  
PHYSICAL THERAPY

 **APTA**  
American Physical Therapy Association

---

## REFERENCES

1. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. *Clin Pharmacokinet*. 1981;6(6):429-453.
2. Ross EM, Kenakin TP. Pharmacodynamics. In: Hardman JG, Limbird LE, Gilman AG, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 10th ed. New York, NY: McGraw-Hill, Medical Publishing Division; 2001:31-45.
3. Duggan AW, North RA. Electrophysiology of opioids. *Pharmacol Rev*. 1983;35(4):219-281.
4. Goodman RR, Pasternak GW. Visualization of mu1 opiate receptors in rat brain by using a computerized autoradiographic subtraction technique. *Proc Natl Acad Sci U S A*. 1985;82(19):6667-6671.
5. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. *Circulation*. 1998;97(14):1411-1420.
6. Roden DM, George AL Jr. The genetic basis of variability in drug responses. *Nat Rev Drug Discov*. 2002;1(1):37-44.
7. Bourne H, von Zastrow M. Drug receptors and pharmacodynamics. In: Katzung B, ed. *Basic and Clinical Pharmacology*. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004:11-33.
8. Katzung B, ed. *Basic and Clinical Pharmacology*. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004.
9. Hardman JG, Limbird LE, Gilman AG, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 10th ed. New York, NY: McGraw-Hill, Medical Publishing Division; 2001.
10. Walle T, Webb JG, Bagwell EE, Walle UK, Daniell HB, Gaffney TE. Stereoselective delivery and actions of beta receptor antagonists. *Biochem Pharmacol*. 1988;37(1):115-124.
11. World Health Organization. *Technical Report Series*. Geneva, Switzerland: World Health Organization; 1966.
12. Oates JA. The science of drug therapy. In: Brunton LL, Lazo JS, Parker KL, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 11th ed. New York, NY: McGraw-Hill, Medical Publishing Division; 2006:117-136.
13. Reuter I, Harder S, Engelhardt M, Baas H. The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. *Mov Disord*. 2000;15(5):862-868.
14. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. *Clin Pharmacol Ther*. 1999;66(6):594-601.
15. Hinderling PH, Tendolkar A, Dee CM, Barr WH, Seibeling M, Duerr H. Single-dose interaction study of diprafe-
- none HCl and propranolol HCl in healthy volunteers. *J Clin Pharmacol*. 1995;35(7):721-729.
16. Buxton ILO. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action and elimination. In: Brunton LL, Lazo JS, Parker KL, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 11th ed. New York, NY: McGraw-Hill, Medical Publishing Division; 2006:1-39.
17. Flynn EJ. Pharmacodynamic and pharmacokinetic principles of pharmacology and drug therapy. *J Neurol Phys Ther*. 2003;27:93-100.
18. Cross JH. Reevaluation of the employment of Fick's law for diffusion dosimeters. *Environ Sci Technol*. 2003;37(8):1633-1638.
19. Duhlmeier R, Hacker A, Widdel A, von Engelhardt W, Sallmann HP. Mechanisms of insulin-dependent glucose transport into porcine and bovine skeletal muscle. *Am J Physiol Regul Integr Comp Physiol*. 2005;289(1):R187-R197.
20. Holford NHG. Pharmacokinetics and pharmacodynamics: rational dosing and the time course of drug action. In: Katzung B, ed. *Basic and Clinical Pharmacology*. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004:34-50.
21. Potts RO, Lobo RA. Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist. *Obstet Gynecol*. 2005;105(5 pt 1):953-961.
22. Correia M. Drug biotransformation. In: Katzung B, ed. *Basic and Clinical Pharmacology*. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004:51-63.
23. Dossing M. Effect of acute and chronic exercise on hepatic drug metabolism. *Clin Pharmacokinet*. 1985;10(5):426-431.
24. Lenz TL, Lenz NJ, Faulkner MA. Potential interactions between exercise and drug therapy. *Sports Med*. 2004;34(5):293-306.
25. McArdle WD, Katch FL, Katch VL. *Exercise Physiology, Energy, Nutrition and Human Performance*. 3rd ed. Philadelphia, PA: Lea & Febiger; 1991.
26. Brouns F, Saris WH, Rehrer NJ. Abdominal complaints and gastrointestinal function during long-lasting exercise. *Int J Sports Med*. 1987;8(3):175-189.
27. Cordain L, Latin RW, Behnke JJ. The effects of an aerobic running program on bowel transit time. *J Sports Med Phys Fitness*. 1986;26(1):101-104.
28. Klemsdal TO, Gjesdal K, Bredesen JE. Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin. *Eur J Clin Pharmacol*. 1992;43(6):625-628.

29. van Baak MA. Influence of exercise on the pharmacokinetics of drugs. *Clin Pharmacokinet*. 1990;19(1):32-43.
30. Villa JG, Bayon JE, Gonzalez-Gallego J. Changes in metabolism and urinary excretion of antipyrine induced by aerobic conditioning. *J Sports Med Phys Fitness*. 1999;39(3):197-201.
31. Stoschitzky K, Lindner W, Klein W. Stereoselective release of (S)-atenolol from adrenergic nerve endings at exercise. *Lancet*. 1992;340(8821):696-697.
32. Ylitalo P, Hinkka H. Effect of exercise on plasma levels and urinary excretion of sulphadimidine and procainamide. *Int J Clin Pharmacol Ther Toxicol*. 1985;23(10):548-553.
33. Ciccone CD. Basic pharmacokinetics and the potential effect of physical therapy interventions on pharmacokinetic variables. *Phys Ther*. 1995;75(5):343-351.